Figure 4.

Schematic outline of cytokine release from rhIL-1β and LPS-stimulated PBMC, and cytokine inhibition orchestrated by the effect of ST2825. For illustrative purposes, we performed a representative figure to summarise our results. On the left side of this illustration, inflammatory cytokine release from LPS-stimulated PBMC is presented. On the right side of the illustration, inflammatory cytokine release from rhIL-1β-stimulated PBMC is presented. For both cases, the pro- and anti-inflammatory cytokine profiles are indicated in red and blue, respectively. The cytokines inhibited by effect of ST2825 are indicated with curly braces. LPS, lipopolysaccharide; TLR, toll-like receptor 4; MD2, myeloid differentiation factor 2; IL-1β, interleukin-1 beta; IL-1RI, IL-1 receptor type I; IL-1RAcP, interleukin 1 receptor accessory protein. TIR, toll-IL-1-receptor domains; MyD88, myeloid differentiation primary response 88. ST2825, MyD88 dimerisation inhibitor.